谷歌浏览器插件
订阅小程序
在清言上使用

Comparable Safety And Immunogenicity And Sustained Efficacy After Transition To Sb2 (An Infliximab Biosimilar) Vs Ongoing Reference Infliximab (Remicade (R)) In Patients With Rheumatoid Arthritis: Results Of Phase Iii Transition Study

ARTHRITIS & RHEUMATOLOGY(2016)

引用 0|浏览19
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要